SUVEN Stock Overview
Suven Life Sciences Limited, a clinical-stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel therapeutics for the treatment of neurodegenerative disorders in India, the United States, Europe, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Suven Life Sciences Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹115.70 |
| 52 Week High | ₹129.00 |
| 52 Week Low | ₹55.00 |
| Beta | 1.51 |
| 1 Month Change | 13.93% |
| 3 Month Change | -3.66% |
| 1 Year Change | 105.69% |
| 3 Year Change | 31.03% |
| 5 Year Change | -57.51% |
| Change since IPO | -66.75% |
Recent News & Updates
Recent updates
Shareholder Returns
| SUVEN | IN Life Sciences | IN Market | |
|---|---|---|---|
| 7D | 3.1% | 1.1% | -0.03% |
| 1Y | 105.7% | 20.7% | 46.9% |
Return vs Industry: SUVEN exceeded the Indian Life Sciences industry which returned 20.7% over the past year.
Return vs Market: SUVEN exceeded the Indian Market which returned 46.9% over the past year.
Price Volatility
| SUVEN volatility | |
|---|---|
| SUVEN Average Weekly Movement | 6.6% |
| Life Sciences Industry Average Movement | 6.2% |
| Market Average Movement | 6.8% |
| 10% most volatile stocks in IN Market | 10.1% |
| 10% least volatile stocks in IN Market | 4.2% |
Stable Share Price: SUVEN has not had significant price volatility in the past 3 months.
Volatility Over Time: SUVEN's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1989 | 132 | Venkat Jasti | www.suven.com |
Suven Life Sciences Limited, a clinical-stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel therapeutics for the treatment of neurodegenerative disorders in India, the United States, Europe, and internationally. The company engages in drug discovery and development of new chemical entities (NCEs) in central nervous system therapies. Its product candidates include Masupirdine (SUVN-502) for the treatment of Alzheimer disease and neuropsychiatric symptoms; Samelisant (SUVN-G3031), a potent and selective histamine H3 receptor inverse agonist for the treatment of sleep and cognitive disorders; and Ropanicant (SUVN-911), a novel, potent, and selective a4ß2 nicotinic acetylcholine receptor antagonist for the treatment of depressive disorders.
Suven Life Sciences Limited Fundamentals Summary
| SUVEN fundamental statistics | |
|---|---|
| Market cap | ₹24.96b |
| Earnings (TTM) | -₹1.06b |
| Revenue (TTM) | ₹119.74m |
208.5x
P/S Ratio-23.5x
P/E RatioIs SUVEN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SUVEN income statement (TTM) | |
|---|---|
| Revenue | ₹119.74m |
| Cost of Revenue | ₹5.66m |
| Gross Profit | ₹114.09m |
| Other Expenses | ₹1.18b |
| Earnings | -₹1.06b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 15, 2024
| Earnings per share (EPS) | -4.87 |
| Gross Margin | 95.28% |
| Net Profit Margin | -886.73% |
| Debt/Equity Ratio | 0.3% |
How did SUVEN perform over the long term?
See historical performance and comparison